Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Trobix Bio logo — PIONEERING PRECISION HUMAN MICROBIOME THERAPEUTICS

Trobix Bio

PIONEERING PRECISION HUMAN MICROBIOME THERAPEUTICS

Founded 2018 Israel Israel 7 employees Series A Total: $6.00M Biotechnology, Pharmaceutical

General Information

Company Name Trobix Bio
Founded Year 2018
Location Israel Israel +1
Employees 7
Industries Biotechnology, Pharmaceutical
Funding Stage Series A
Social

Get notified when Trobix Bio moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Trobix Bio

Trobix Bio is a biotechnology and pharmaceutical company based in Israel that was founded in 2018. The company's slogan, "PIONEERING PRECISION HUMAN MICROBIOME THERAPEUTICS," encapsulates its core focus on leveraging the TBX™ technology platform. This platform integrates CRISPR, phage, and synthetic biology to re-program specific activities in targeted microbiome bacteria, aiming to discover and develop orally administered precision oncology therapeutics.

The company recently received a significant $3.00M Series A investment on 30 March 2023 from Chartered Investment, marking an important milestone in its growth and development. This injection of capital is poised to propel Trobix Bio to further refine and expand its pioneering work in the field of human microbiome therapeutics.

Taxonomy: Microbiome therapeutics, Precision medicine, CRISPR, Phage therapy, Synthetic biology, Oncology therapeutics, Antibacterial products, Platform technologies, ActiSense, GOTrap, Antimicrobial resistance, Precision healthcare, Innovation, Biopharmaceuticals

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series A •••••• 1
Investor
30 Mar 2023
Series A •••••• 1
Investor
29 Jul 2020

Trobix Bio Alternatives & Competitors

Trobix Bio vs
ImmunoBiome Inc.
ImmunoBiome Inc.

Microbiome-Targeted Therapeutics for Intractable Immune Diseases.

Trobix Bio vs
DermBiont, Inc.
DermBiont, Inc. United States

Advancing targeted topical therapeutics for dermatological indications

Series A
18 employees
Biotechnology, Health Care
Trobix Bio vs
Autonomous Therapeutics
Autonomous Therapeutics United States

Precision medicines via a new class of RNA

11 employees
Biotechnology, Prop Tech

FAQ About Trobix Bio

PIONEERING PRECISION HUMAN MICROBIOME THERAPEUTICS
Trobix Bio was founded in 2018.
Trobix Bio is headquartered in Israel.
Trobix Bio operates in the following industries: Biotechnology, Pharmaceutical.
Trobix Bio has approximately 7 employees.
Trobix Bio has completed 2 funding rounds, raising a total of $6.00M. The latest funding stage is Series A.
Top alternatives and competitors to Trobix Bio include ImmunoBiome Inc., DermBiont, Inc., Autonomous Therapeutics, CC Bio, Nexbiome Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Trobix Bio and ImmunoBiome Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Trobix Bio and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes